Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes

English version České info

Background:
Atypical antipsychotic medications are widely prescribed for the adjunctive treatment of depression, yet their total risk–benefit profile is not well understood. We thus conducted a systematic review of the efficacy and safety profiles of atypical antipsychotic medications used for the adjunctive treatment of depression.

Methods and Findings:
We included randomized trials comparing adjunctive antipsychotic medication to placebo for treatment-resistant depression in adults. Our literature search (conducted in December 2011 and updated on December 14, 2012) identified 14 short-term trials of aripiprazole, olanzapine/fluoxetine combination (OFC), quetiapine, and risperidone. When possible, we supplemented published literature with data from manufacturers' clinical trial registries and US Food and Drug Administration New Drug Applications. Study duration ranged from 4 to 12 wk. All four drugs had statistically significant effects on remission, as follows: aripiprazole (odds ratio [OR], 2.01; 95% CI, 1.48–2.73), OFC (OR, 1.42; 95% CI, 1.01–2.0), quetiapine (OR, 1.79; 95% CI, 1.33–2.42), and risperidone (OR, 2.37; 95% CI, 1.31–4.30).

The number needed to treat (NNT) was 19 for OFC and nine for each other drug. All drugs with the exception of OFC also had statistically significant effects on response rates, as follows: aripiprazole (OR, 2.07; 95% CI, 1.58–2.72; NNT, 7), OFC (OR, 1.30, 95% CI, 0.87–1.93), quetiapine (OR, 1.53, 95% CI, 1.17–2.0; NNT, 10), and risperidone (OR, 1.83, 95% CI, 1.16–2.88; NNT, 8). All four drugs showed statistically significant effects on clinician-rated depression severity measures (Hedges' g ranged from 0.26 to 0.48; mean difference of 2.69 points on the Montgomery–Asberg Depression Rating Scale across drugs). On measures of functioning and quality of life, these medications produced either no benefit or a very small benefit, except for risperidone, which had a small-to-moderate effect on quality of life (g = 0.49).

Treatment was linked to several adverse events, including akathisia (aripiprazole), sedation (quetiapine, OFC, and aripiprazole), abnormal metabolic laboratory results (quetiapine and OFC), and weight gain (all four drugs, especially OFC). Shortcomings in study design and data reporting, as well as use of post hoc analyses, may have inflated the apparent benefits of treatment and reduced the apparent incidence of adverse events.

Conclusions:
Atypical antipsychotic medications for the adjunctive treatment of depression are efficacious in reducing observer-rated depressive symptoms, but clinicians should interpret these findings cautiously in light of (1) the small-to-moderate-sized benefits, (2) the lack of benefit with regards to quality of life or functional impairment, and (3) the abundant evidence of potential treatment-related harm.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes. PLoS Med 10(3): e32767. doi:10.1371/journal.pmed.1001403
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001403

Souhrn

Zdroje

1. AlexanderGC, GallagherSA, MascolaA, MoloneyRM, StaffordRS (2011) Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf 20: 177–184.

2. SigalE (2009) Bristol-Myers Squibb Company Q1 2009 earnings call transcript. Seeking Alpha Available: http://seekingalpha.com/article/133733-bristol-myers-squibb-company-q1-2009-earnings-call-transcript?part=qanda. Accessed 7 May 2009.

3. OlfsonM, MarcusSC (2009) National patterns in antidepressant medication treatment. Arch Gen Psychiatry 66: 848–856.

4. GelladWF, AspinallSL, HandlerSM, StoneRA, CastleN, et al. (2012) Use of antipsychotics among older residents in VA nursing homes. Med Care 50: 954–960.

5. LeslieDL, MohamedS, RosenheckRA (2009) Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv 60: 1175–1181.

6. NelsonJC, PapakostasGI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166: 980–991.

7. PapakostasGI, SheltonRC, SmithJ, FavaM (2007) Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68: 826–831.

8. SheltonRC, PapakostasGI (2008) Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 117: 253–259.

9. KomossaK, DeppingAM, GaudchauA, KisslingW, LeuchtS (2010) Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010: CD008121.

10. TurnerEH, MatthewsAM, LinardatosE, TellRA, RosenthalR (2008) Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358: 252–260.

11. TurnerEH, KnoepflmacherD, ShapleyL (2012) Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database. PLoS Med 9: e1001189 doi:10.1371/journal.pmed.1001189.

12. EydingD, LelgemannM, GrouvenU, HarterM, KrompM, et al. (2010) Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 341: c4737.

13. KirkhamJJ, DwanKM, AltmanDG, GambleC, DoddS, et al. (2010) The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 340: c365.

14. IshakWW, GreenbergJM, BalayanK, KapitanskiN, JeffreyJ, et al. (2011) Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry 19: 229–239.

15. BechP (2005) Social functioning: should it become an endpoint in trials of antidepressants? CNS Drugs 19: 313–324.

16. HealyD (2000) The assessment of outcomes in depression: measures of social functioning. Rev Contemp Pharmacother 11: 295–301.

17. TsaiAC, RosenlichtNZ, JureidiniJN, ParryPI, SpielmansGI, et al. (2011) Aripiprazole in the maintenance treatment of bipolar disorder: a critical review of the evidence and its dissemination into the scientific literature. PLoS Med 8: 1–13 doi:10.1371/journal.pmed.1000434.

18. GoodwinFK, WhithamEA, GhaemiSN (2011) Maintenance treatment study designs in bipolar disorder: do they demonstrate that atypical neuroleptics (antipsychotics) are mood stabilizers? CNS Drugs 25: 819–827.

19. Montejo-GonzalezAL, LlorcaG, IzquierdoJA, LedesmaA, BousonoM, et al. (1997) SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23: 176–194.

20. ZimmermanM, GalioneJN, AttiullahN, FriedmanM, TobaC, et al. (2010) Underrecognition of clinically significant side effects in depressed outpatients. J Clin Psychiatry 71: 484–490.

21. SavovicJ, JonesHE, AltmanDG, HarrisRJ, JuniP, et al. (2012) Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med 157: 429–438.

22. SchulzKF, AltmanDG, MoherD (2010) CONSORT Group (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 7: e1000251 doi:10.1371/journal.pmed.1000251.

23. MontgomeryS, AsbergM (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389.

24. HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg 23: 56–61.

25. CoryaSA, WilliamsonD, SangerTM, BriggsSD, CaseM, et al. (2006) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23: 364–372.

26. SheltonRC, WilliamsonDJ, CoryaSA, SangerTM, Van CampenLE, et al. (2005) Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 66: 1289–1297.

27. SheltonRC, TollefsonGD, TohenM, StahlS, GannonKS, et al. (2001) A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158: 131–134.

28. FrankE, PrienRF, JarrettRB, KellerMB, KupferDJ, et al. (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48: 851–855.

29. RushAJ, GilesDE, SchlesserMA, FultonCL, WeissenburgerJ, et al. (1986) The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 18: 65–87.

30. EndicottJ, NeeJ, HarrisonW, BlumenthalR (1993) Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull 29: 321–326.

31. WareJ, SherbourneCD (1992) The MOS 36-item short-form health survey (SF-36). Med Care 30: 473–483.

32. SheehanD, Harnett-SheehanK, RajB (1996) The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3) 89–95.

33. Hedges LV, Olkin I (1985) Statistical methods for meta-analysis. San Diego: Academic Press.

34. LaupacisA, SackettDL, RobertsRS (1988) An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318: 1728–1733.

35. DeeksJJ (2002) Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med 21: 1575–1600.

36. Cates CJ (2012) Visual RX, version 3 [computer program]. Available: http://www.nntonline.net/visualrx/. Accessed 2 September 2012.

37. HigginsJPT, ThompsonSG, DeeksJJ, AltmanDG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557–560.

38. DerSimonianR, LairdN (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.

39. HigginsJPT, ThompsonSG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539–1558.

40. Biostat (2010) Comprehensive meta-analysis. Version 2.2.057, Englewood, NJ.

41. DuvalS, TweedieR (2000) A nonparametric “trim and fill” method of accounting for publication bias in meta-analysis. J Am Stat Assoc 95: 89–98.

42. FavaM, MischoulonD, IosifescuD, WitteJ, PencinaM, et al. (2012) A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A study). Psychother Psychosom 81: 87–97.

43. NeyeloffJL, FuchsSC, MoreiraLB (2012) Meta-analyses and forest plots using a Microsoft Excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes 5: 52.

44. MahmoudRA, PandinaGJ, TurkozI, Kosik-GonzalezC, CanusoCM, et al. (2007) Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 147: 593–602.

45. Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edition. Hillsdale (New Jersey): Erlbaum.

46. KirschI, DeaconBJ, Huedo-MedinaTB, ScoboriaA, MooreTJ, et al. (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5: e45 doi:10.1371/journal.pmed.0050045.

47. MoncrieffJ, KirschI (2005) Efficacy of antidepressants in adults. BMJ 331: 155–157.

48. TurnerEH, RosenthalR (2008) Efficacy of antidepressants. BMJ 336: 516–517.

49. BauerM, El-KhaliliN, DattoC, SzamosiJ, ErikssonH (2010) A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 127: 19–30.

50. RushAJ, KraemerHC, SackeimHA, FavaM, TrivediMH, et al. (2006) Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology 31: 1841–1853.

51. KirschI, MoncrieffJ (2007) Clinical trials and the response rate illusion. Contemp Clin Trials 28: 348–351.

52. ClinicalTrials.gov (2011) Study comparing adjunctive risperidone versus placebo in major depressive disorder that is not responding to standard therapy. Available: http://clinicaltrials.gov/ct2/show/NCT00095134. Accessed 6 February 2013.

53. RapaportMH, GharabawiGM, CanusoCM, MahmoudRA, KellerMB, et al. (2007) Corrigendum: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 32: 1208.

54. CarrollB (2009) Aripiprazole in refractory depression? J Clin Psychopharmacol 29: 90–91.

55. McKnightPE, KashdanTB (2009) The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev 29: 243–259.

56. BechP, TanghøjP, CialdellaP, AndersenHF, PedersenAG (2004) Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol 7: 283–290.

57. DunlopBW, ReddyS, YangL, LubaczewskiS, FochtK, et al. (2011) Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol 31: 569–576.

58. HewettK, ChrzanowskiW, SchmitzM, SavelaA, MilanovaV, et al. (2009) Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 23: 531–538.

59. HewettK, GeeMD, KrishenA, WunderlichH, Le ClusA, et al. (2010) Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 24: 1209–1216.

60. ZajeckaJ, SchatzbergA, StahlS, ShahA, CaputoA, et al. (2010) Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 30: 135–144.

61. PapakostasGI, PetersenT, MahalY, MischoulonD, NierenbergAA, et al. (2004) Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry 26: 13–17.

62. DeshauerD, MoherD, FergussonD, MoherE, SampsonM, et al. (2008) Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials. CMAJ 178: 1293–1301.

63. CatesCJ (2002) Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol 2: 1.

64. BahrickAS, HarrisMM (2009) Sexual side effects of antidepressant medications: an informed consent-accountability gap. J Contemp Psychother 39: 135–143.

65. BalonR (2006) SSRI-associated sexual dysfunction. Am J Psychiatry 163: 1504–1509.

66. BentS, PadulaA, AvinsAL (2006) Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med 144: 257–261.

67. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Center for Biologics Evaluation and Research (2006) Guidance for industry: adverse reactions section of labeling for human prescription drug and biological products—content and format. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075057.pdf. Accessed 4 September 2012.

68. BaşoğluM, MarksI, LivanouM, SwinsonR (1997) Double-blindness procedures, rater blindness, and ratings of outcome. Observations from a controlled trial. Arch Gen Psychiatry 54: 744–748.

69. WisnerKL, PerelJM, PeindlKS, HanusaBH, FindlingRL, et al. (2001) Prevention of recurrent postpartum depression: a randomized clinical trial. J Clin Psychiatry 62: 82–86.

70. PerlisRH, OstacherM, FavaM, NierenbergAA, SachsGS, et al. (2010) Assuring that double-blind is blind. Am J Psychiatry 167: 250–252.

71. MoncrieffJ, WesselyS, HardyR (1998) Meta-analysis of trials comparing antidepressants with active placebos. Br J Psychiatry 172: 227–231.

72. HrobjartssonA, ForfangE, HaahrM, Als-NielsenB, BrorsonB (2007) Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol 36: 654–663.

73. KeitnerGI, GarlowSJ, RyanCE, NinanPT, SolomonDA, et al. (2009) A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 43: 205–214.

74. Zhang J, Mahjoob K, Yang P (2007) Statistical review and evaluation. NDA 21-436/S_018. Abilify (aripiprazole). Aripiprazole as adjunctive treatment of major depressive disorder. Center for Drug Evaluation and Research. Available: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021436s018_StatR.pdf. Accessed 10 January 2012.

75. BermanRM, MarcusRN, SwaninkR, McQuadeRD, CarsonWH, et al. (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68: 843–853.

76. MarcusRN, McQuadeRD, CarsonWH, HennickenD, FavaM, et al. (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28: 156–165.

77. ReevesH, BatraS, MayRS, ZhangR, DahlDC, et al. (2008) Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry 69: 1228–1336.

78. KjaergardLL, VillumsenJ, GluudC (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135: 982.

79. TsaiAC (2009) Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: comments on article by Marcus et al. J Clin Psychopharmacol 29: 91–2; author reply 92-3.

80. DwanK, AltmanDG, ArnaizJA, BloomJ, ChanAW, et al. (2008) Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 3: e3081 doi:10.1371/journal.pone.0003081.

81. BauerM, PretoriusHW, ConstantEL, EarleyWR, SzamosiJ, et al. (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70: 540–549.

82. BermanRM, FavaM, ThaseME, TrivediMH, SwaninkR, et al. (2009) Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14: 197–206.

83. El-KhaliliN, JoyceM, AtkinsonS, BuynakRJ, DattoC, et al. (2010) Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 13: 917–932.

84. McIntyreA, GendronA, McIntyreA (2007) Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 24: 487–494.

85. ThaseME, CoryaSA, OsuntokunO, CaseM, HenleyDB, et al. (2007) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry 68: 224–236.